Jain Mili, Tripathi Anil
a Pathology Department , King George's Medical University , Lucknow , Uttar Pradesh , India.
Expert Rev Hematol. 2017 Oct;10(10):915-920. doi: 10.1080/17474086.2017.1371588. Epub 2017 Sep 1.
Patients presenting with idiopathic cytopenia with non-diagnostic marrow morphology and a normal karyotype pose a diagnostic and therapeutic challenge. Additional diagnostic information from mutation analysis could provide important clinical insights. However, one has to be cautious during such diagnostic interpretations in view of the recent documentation of clonal somatic mutations in healthy elder individuals. Whether to regard clonality synonymous with malignant proliferation or a manifestation of ageing process is to be judged carefully. Areas covered: The review covers defining criteria and diagnostic work up for Idiopathic cytopenia of undetermined significance (ICUS), Clonal cytopenia of undetermined significance (CCUS), Clonal hematopoiesis of indeterminate potential (CHIP). It also presents the results from previous reports on this subject. In addition the evolution and potential impact of these entities is discussed. Expert commentary: Current evidence does not support the use of somatic mutations as presumptive evidence of myelodysplastic syndrome (MDS). Including CCUS under the category of MDS requires further insight on natural disease course. Longitudinal follow up study on ICUS, CCUS, CHIP may eventually identify the pathological significance of the clonal mutations. An absence of mutation however may still be useful as good predictor of not having MDS.
患有特发性血细胞减少症、骨髓形态学诊断不明确且核型正常的患者面临着诊断和治疗挑战。来自突变分析的额外诊断信息可能提供重要的临床见解。然而,鉴于最近在健康老年个体中记录到克隆性体细胞突变,在进行此类诊断解释时必须谨慎。是将克隆性视为与恶性增殖同义还是衰老过程的一种表现,需要仔细判断。涵盖领域:本综述涵盖意义未明的特发性血细胞减少症(ICUS)、意义未明的克隆性血细胞减少症(CCUS)、潜能未明的克隆性造血(CHIP)的定义标准和诊断检查。它还展示了此前关于该主题的报告结果。此外,还讨论了这些实体的演变及其潜在影响。专家评论:目前的证据不支持将体细胞突变用作骨髓增生异常综合征(MDS)的推定证据。将CCUS纳入MDS类别需要对疾病自然进程有进一步的了解。对ICUS、CCUS、CHIP进行纵向随访研究最终可能确定克隆性突变的病理意义。然而,没有突变仍可能是没有患MDS的良好预测指标。